Brookfield Asset Management (BAM) is awaiting information from Grifols (GRFS) about related-party transactions as it seeks to complete its due diligence on the business, Clara Hernanz Lizarraga and Rodrigo Orihuela of Bloomberg report, citing a person familiar with the matter. That’s a key item among several pending issues that have slowed Brookfield’s process of assessing the value of Grifols ahead of a potential takeover bid, a source told Bloomberg. Brookfield is still pursuing a deal and is confident it has a path to fund a transaction, the person added. Shares of Grifols are up 25c to $9.05 following the report.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRFS:
- Brookfield still pursuing Grifols deal, Bloomberg reports
- Grifols SA (GRFS) Q3 Earnings Cheat Sheet
- Grifols price target lowered to EUR 15.50 from EUR 15.60 at Berenberg
- Grifols receives FDA approval to treat surgical bleeding with FS solution
- Grifols partners with BARDA for PoC testing of ocular immunoglobulin